SCHEMBL26200048

SCHEMBL26200048

Cn1ncc2c(C(C)(C)C)cc(Cl)cc21

nearest known ligand 0.35

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CCR4 P51679 1/20 0.32
TRPV1 Q8NER1 2/20 0.32
PDE2A O00408 1/20 0.32
LRRK2 Q5S007 1/20 0.32
HPGD P15428 3/20 0.31
HSD17B10 Q99714 2/20 0.31
HTT P42858 1/20 0.31
MEN1 O00255 2/20 0.31
KMT2A Q03164 2/20 0.31
MAPT P10636 2/20 0.30
KDM4E B2RXH2 1/20 0.30
CYP1A2 P05177 1/20 0.30
POLB P06746 1/20 0.30
HSP90AA1 P07900 1/20 0.30
CYP3A4 P08684 1/20 0.30
CYP2C9 P11712 1/20 0.30
MAPK1 P28482 1/20 0.30
CYP2C19 P33261 1/20 0.30
TRPA1 O75762 1/20 0.30
ALDH1A1 P00352 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15730130 0.78 PDE2A (0.39) CCR4PDE2AHPGDHSD17B10HTT
SCHEMBL24104233 0.77 ADORA2A (0.35) CCR4PDE2AHPGDHSD17B10HTT
SCHEMBL31479523 0.75 MEN1 (0.41) CCR4PDE2AHPGDHSD17B10HTT
SCHEMBL21047086 0.75 MEN1 (0.41) CCR4PDE2AHPGDHSD17B10HTT
SCHEMBL21046782 0.73 CCR4 (0.39) CCR4PDE2AHPGDHSD17B10HTT
SCHEMBL25950689 0.73 PI4KA (0.31) CYP3A4CYP2C9
SCHEMBL2627064 0.71 CCR4 (0.42) CCR4TRPV1HPGDHTTCYP3A4
SCHEMBL25950806 0.70 CCR4 (0.33) CCR4MAPTKDM4EALDH1A1
SCHEMBL24654997 0.68 KMT2A (0.41) PDE2AHPGDHSD17B10MEN1KMT2A
SCHEMBL16626052 0.68 POLB (0.36) TRPV1HPGDHTTPOLBALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230271939-A1 4-ETHYNYLPYRIDINE DERIVATIVES USEFUL AS GCN2 INHIBITORS IP2IPO INNOVATIONS LIMITED (GB) 2023-08-31 US disclosed
US-20230271939-A1 4-ETHYNYLPYRIDINE DERIVATIVES USEFUL AS GCN2 INHIBITORS IP2IPO INNOVATIONS LIMITED (GB) 2023-08-31 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230271939-A1 4-ETHYNYLPYRIDINE DERIVATIVES USEFUL AS GCN2 INHIBITORS EIF2AK4, GCN1, EIF5B CCR4 1626/4885TRPV1 3626/4885PDE2A 1465/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.